Fianlimab
Fianlimab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Fianlimab Usage And Synthesis
Uses
Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity[1].
in vivo
Fianlimab (5-25 mg/kg, ip, twice a week for 2 weeks) exhibits protective effect against MC38.Ova colon cancer, inhibits tumor growth with the combination of Cemiplimab (HY-P99203) in mouse models[2].
| Animal Model: | Mouse MC38.Ova colon cancer cell xenograft model[2] |
| Dosage: | 5-25 mg/kg |
| Administration: | ip, twice a week for 2 weeks |
| Result: | Inhibited tumor growth, increased the concentrations of IFNγ, TNFα, and IL10 in serum and spleen. |
References
[1] Omid Hamid, et al. Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.Meeting Abstract | 2021 ASCO Annual Meeting I.
[2] Burova E, et al., Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice. Mol Cancer Ther. 2019 Nov;18(11):2051-2062. DOI:10.1158/1535-7163.MCT-18-1376
FianlimabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 4008200310
- marketing@tsbiochem.com